SSMX.Y Stock Overview
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for SSMX.Y from our risk checks.
Sysmex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥16.01 |
| 52 Week High | JP¥24.38 |
| 52 Week Low | JP¥14.79 |
| Beta | 0.52 |
| 1 Month Change | -11.15% |
| 3 Month Change | -18.26% |
| 1 Year Change | -27.60% |
| 3 Year Change | -53.88% |
| 5 Year Change | -12.00% |
| Change since IPO | 182.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| SSMX.Y | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.1% | -2.4% | -1.7% |
| 1Y | -27.6% | 3.6% | 22.9% |
Return vs Industry: SSMX.Y underperformed the US Medical Equipment industry which returned 3.6% over the past year.
Return vs Market: SSMX.Y underperformed the US Market which returned 22.9% over the past year.
Price Volatility
| SSMX.Y volatility | |
|---|---|
| SSMX.Y Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SSMX.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: SSMX.Y's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 9,500 | Hisashi Ietsugu | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Sysmex Corporation Fundamentals Summary
| SSMX.Y fundamental statistics | |
|---|---|
| Market cap | US$10.17b |
| Earnings (TTM) | US$294.07m |
| Revenue (TTM) | US$2.86b |
34.6x
P/E Ratio3.6x
P/S RatioIs SSMX.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SSMX.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥438.28b |
| Cost of Revenue | JP¥205.29b |
| Gross Profit | JP¥232.99b |
| Other Expenses | JP¥187.93b |
| Earnings | JP¥45.06b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 72.28 |
| Gross Margin | 53.16% |
| Net Profit Margin | 10.28% |
| Debt/Equity Ratio | 6.1% |
How did SSMX.Y perform over the long term?
See historical performance and comparison